PT Royal Prima Tbk (PRIM.JK)
IDR 57.0
(0.0%)
IDR 57.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 52.4 Billion IDR | 51.88% |
| 2022 | 67.04 Billion IDR | -66.79% |
| 2021 | 140.64 Billion IDR | 82.65% |
| 2020 | 74.46 Billion IDR | 400.32% |
| 2019 | 29.5 Billion IDR | -54.23% |
| 2018 | 38.8 Billion IDR | -10.63% |
| 2017 | 29.5 Billion IDR | 75.34% |
| 2016 | 15.88 Billion IDR | 517.02% |
| 2015 | 2.64 Billion IDR | 173.89% |
| 2014 | -3.37 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.23 Billion IDR | -129.81% |
| 2024 Q3 | 5.42 Billion IDR | 579.75% |
| 2024 Q1 | -3.73 Billion IDR | -90.19% |
| 2023 Q4 | 38.34 Billion IDR | 3063.56% |
| 2023 FY | - IDR | 51.88% |
| 2023 Q1 | -6.68 Billion IDR | -152.89% |
| 2023 Q3 | 1.21 Billion IDR | 121.27% |
| 2023 Q2 | -5.69 Billion IDR | 14.76% |
| 2022 Q1 | 5.57 Billion IDR | 117.68% |
| 2022 Q3 | 6.45 Billion IDR | -26.96% |
| 2022 Q4 | 12.64 Billion IDR | 95.78% |
| 2022 FY | - IDR | -66.79% |
| 2022 Q2 | 8.83 Billion IDR | 58.42% |
| 2021 FY | - IDR | 82.65% |
| 2021 Q1 | 21.8 Billion IDR | -17.16% |
| 2021 Q2 | 53.26 Billion IDR | 144.27% |
| 2021 Q3 | 62.01 Billion IDR | 16.42% |
| 2021 Q4 | -31.55 Billion IDR | -150.88% |
| 2020 Q3 | 22.29 Billion IDR | 1085.2% |
| 2020 Q2 | 1.88 Billion IDR | -60.39% |
| 2020 Q1 | 4.75 Billion IDR | 159.58% |
| 2020 FY | - IDR | 400.32% |
| 2020 Q4 | 26.32 Billion IDR | 18.05% |
| 2019 Q1 | 4.64 Billion IDR | -4.8% |
| 2019 FY | - IDR | -54.23% |
| 2019 Q4 | 1.83 Billion IDR | -25.76% |
| 2019 Q3 | 2.46 Billion IDR | 17.39% |
| 2019 Q2 | 2.09 Billion IDR | -54.82% |
| 2018 FY | - IDR | -10.63% |
| 2018 Q1 | 6.61 Billion IDR | 164.71% |
| 2018 Q2 | 4.23 Billion IDR | -35.95% |
| 2018 Q3 | 8.39 Billion IDR | 98.01% |
| 2018 Q4 | 4.88 Billion IDR | -41.81% |
| 2017 Q1 | 9.45 Billion IDR | 0.0% |
| 2017 Q4 | -10.22 Billion IDR | -155.46% |
| 2017 Q2 | 9.45 Billion IDR | 0.0% |
| 2017 Q3 | 18.43 Billion IDR | 94.96% |
| 2017 FY | - IDR | 75.34% |
| 2016 FY | - IDR | 517.02% |
| 2015 FY | - IDR | 173.89% |
| 2014 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Bundamedik Tbk | 223.9 Billion IDR | 76.594% |
| PT Metro Healthcare Indonesia Tbk | -7.68 Billion IDR | 782.376% |
| PT Medikaloka Hermina Tbk | 1584.42 Billion IDR | 96.692% |
| PT Mitra Keluarga Karyasehat Tbk | 1555.38 Billion IDR | 96.631% |
| PT Murni Sadar Tbk | 155.6 Billion IDR | 66.32% |
| PT Famon Awal Bros Sedaya Tbk | 443.01 Billion IDR | 88.17% |
| PT Kedoya Adyaraya Tbk | 61.12 Billion IDR | 14.257% |
| PT Sarana Meditama Metropolitan Tbk | 323.18 Billion IDR | 83.784% |
| PT Siloam International Hospitals Tbk | 2692.46 Billion IDR | 98.054% |
| PT Sejahteraraya Anugrahjaya Tbk | 437.22 Billion IDR | 88.014% |